Company profile
iPSC Disease Modeling | DefiniGEN
Our iPSC disease modeling services and platform will help you generate a range of metabolic and rare disease phenotypes for all your research needs!
Updated 06 Jun 2026 16:52
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
CS01 | Transaction MzUxNTU1OTg4NWFkaXF6a2N4
Published 12 Apr 2026 14:08
Last confirmation statement made up date
Last accounts made up date
RP04AP01 | Transaction MzQzNDE2NDE3NWFkaXF6a2N4
Published 11 Sep 2024 08:53
RP04SH01 | Transaction MzQzMzQzMjQ0OGFkaXF6a2N4
Published 09 Sep 2024 06:53
SH01 | Transaction MzQzMzQzMjgwMWFkaXF6a2N4
Published 29 Aug 2024 08:59
SH01 | Transaction MzQzMjU5ODAxN2FkaXF6a2N4 | Paper/PDF filed
Published 10 Sep 2024 06:16
AP01 | Transaction MzQzMTk1MzM2OGFkaXF6a2N4 | Paper/PDF filed
Published 12 Sep 2024 06:02
MA | Transaction MzQzMTcwNzY4N2FkaXF6a2N4 | Paper/PDF filed
Published 14 Aug 2024 07:56
RESOLUTIONS | Transaction WUQ5M1IwOFphZGlxemtjeA | Paper/PDF filed
Published 14 Aug 2024 07:56
Company registered at Companies House
DefiniGEN was founded in April 2013 to industrialize the OptiDIFF stem cell production platform developed at the University of Cambridge, UK. DefiniGEN builds on intellectual property and knowledge resident at the University of Cambridge Regenerative Medicine Department at Addenbrooke's Hospital and in addition has in-licensed the Yamanaka induced pluripotent stem cell IP portfolio from iPS Academia Japan Inc.
Research and experimental development on biotechnology
DefiniGEN provides a supply of human cell products for preclinical drug development and disease modelling studies.
The company has world-leading expertise in the area of iPSC production and metabolic disease modelling. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products enabling the development of safer and more effective treatments. In addition the technology platform utilises fully defined and humanized conditions required for the development of regenerative medicine cellular therapies.
Supplying chemically-defined medium and hepatocytes produced therefrom for drug discovery and toxicity testing.
1 May 2019 to 30 Apr 2022
Development of an optimised pancreatic cell tool kit to enable accelerated diabetes drug discovery. Diabetes drug discovery is constrained by the lack of availability of human pancreatic islets and their donor-dependent variability. We will develop pancreatic beta cell models for type 2 diabetes research from human induced pluripotent stem cells (hiPSCs),...
1 Jan 2019 to 31 Dec 2020
The aim of this project is to provide cell tools to help scientific researchers working on a common liver disease called non-alcoholic fatty liver disease (NAFLD). The cell products are human liver cells with genetic mutations inserted that ultimately disrupt the function of the cells duplicating NAFLD in the cells, which can be grown in a lab in large qu...
1 Jan 2016 to 30 Jun 2018
Diabetes is a serious condition where the amount of sugar (glucose) in the blood is too high because the body either cannot produce enough of the hormone insulin or cannot use the insulin effectively. There is no known cure for diabetes, and although many treatment options are available, they often do not prevent the disabling long-term complications of t...
1 Jan 2016 to 31 Dec 2017
NASH presents a significant unmet medical need in more economically developed nations, affecting up to 5% of the US population alone. There is currently no medical treatment for NASH, where the condition is a precursor to cirrhosis and hepatocellular carcinoma, conditions with very poor prognoses. One key limiting factor in the development of a treatment ...
